Why is AAV8 the preferred serotype for liver-directed gene therapy studies in NHPs?

AAV8 exhibits potent hepatotropism, meaning it has a natural affinity for liver cells. Foundational research identified its superior gene transfer efficiency to the liver with low pre-existing seroprevalence in human populations. This makes it a primary candidate for therapies targeting hepatic disorders, and non-human primate (NHP) models provide the most translationally relevant system to confirm this tropism and evaluate its safety profile before clinical trials.

What are the primary analytical methods used to quantify AAV8 vector biodistribution in NHP tissues?

A multi-faceted analytical approach is required for a comprehensive IND-enabling data package. The core methods include: 1) Quantitative PCR (qPCR) or droplet digital PCR (ddPCR) to determine vector copy numbers per cell in all collected tissues. 2) Reverse transcription qPCR (RT-qPCR) to measure transgene mRNA expression levels, confirming transcriptional activity. 3) Histology and in situ hybridization (ISH) to visualize vector localization at the cellular level within target and non-target tissues.

How does pre-existing immunity to AAV impact biodistribution study design in NHPs?

Pre-existing neutralizing antibodies (NAbs) against AAV capsids can significantly alter vector biodistribution, leading to rapid clearance and reduced efficacy. All NHPs are screened for NAbs to AAV8 prior to study initiation. Animals selected for studies are typically seronegative or have very low titers to ensure that the observed biodistribution profile accurately reflects the vector’s intrinsic properties, not its interaction with a pre-existing immune response.

Successful Investigational New Drug (IND) applications for liver-directed AAV gene therapies depend on a thorough characterization of vector biodistribution in a translationally relevant large animal model. This page outlines the scientific rationale and core methodologies for conducting AAV8 biodistribution studies in non-human primates (NHPs). Franklin Biolabs executes these GxP-compliant studies to generate the precise, reliable data required to support regulatory submissions within an 18-24 month IND timeline.

Designing IND-Enabling Biodistribution Studies

The design of an NHP biodistribution study must be carefully planned to meet regulatory expectations. This includes defining the route of administration, selecting appropriate dose levels that bracket the intended clinical dose, and establishing a time course for sample collection that can assess both early distribution and long-term persistence.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

All studies are conducted under strict USDA oversight, adhering to the highest standards of animal welfare and the principles of the 3Rs (Replacement, Reduction, and Refinement). For NHP studies, we collaborate with partners who maintain AAALAC accreditation to ensure exemplary care. The resulting data package provides a clear, comprehensive assessment of vector safety and biological activity, directly supporting your program’s progression to the clinic.